Sell-rated reports

287 tickers rated Sell
NewestHighest Score Ranks all reports in this rating group by score, highest first.
Alkermes plc
ALKS·Healthcare
C ★★Sell
Current$44.54
Nov 6, 2026

Alkermes could build a stronger neuroscience franchise through LUMRYZ and alixorexton, but acquisition leverage, weak cash conversion, and uncertain clinical returns limit its current investment appeal.

Score
55
Otter Tail Corporation
OTTR·Industrials
C ★★Sell
Current$83.82
Nov 5, 2026

Otter Tail's regulated utility expansion supports long-term earnings growth and dividends, but declining PVC pipe profitability, heavy capital spending, and a demanding historical valuation weaken the near-term investment case.

Score
55
CRISPR Therapeutics AG
CRSP·Healthcare
C ★★Sell
Current$51.78
Nov 5, 2026

CRISPR Therapeutics offers substantial long-term potential through CASGEVY commercialization and next-generation gene editing, but persistent cash burn, dilution, and uncertain clinical returns weaken the current investment case.

Score
55
Pershing Square Inc.
PS·Financials
C ★★Sell
Current$52.82
Nov 5, 2026

Pershing Square combines a high-margin permanent-capital asset-management franchise with founder-led investment expertise, but its exceptionally demanding earnings valuation leaves shareholders exposed to growth disappointment.

Score
55
Ligand Pharmaceuticals Incorporated
LGND·Healthcare
C ★★Sell
Current$317.00
Nov 2, 2026

Ligand's expanding pharmaceutical royalty portfolio offers strong long-term cash-flow growth potential, but its demanding valuation, acquisition dependence, and financing complexity limit the investment appeal.

Score
55
Molina Healthcare, Inc.
MOH·Healthcare
C ★★Sell
Current$204.78
Oct 31, 2026

Molina Healthcare could recover earnings through higher Medicaid reimbursement rates and improved medical margins, but persistent healthcare cost inflation and declining membership threaten the durability of that recovery.

Score
55
CenterPoint Energy, Inc.
CNP·Utilities
C ★★Sell
Current$42.21
Oct 30, 2026

CenterPoint Energy benefits from durable regulated utility demand and accelerating Houston-area infrastructure investment, but high leverage, persistent negative free cash flow, dilution risk, and a demanding valuation constrain shareholder upside.

Score
55
MSC Industrial Direct Co., Inc.
MSM·Industrials
C ★★Sell
Current$113.86
Oct 26, 2026

MSC Industrial Direct offers a resilient industrial distribution franchise and improving adjusted margins, but demanding valuation, uneven cash conversion, and technology execution risks limit investment appeal.

Score
55
ManpowerGroup Inc.
MAN·Industrials
C ★★Sell
Current$41.22
Oct 20, 2026

ManpowerGroup offers cyclical recovery potential through its established global staffing franchise and discounted valuation, but weak free cash flow and uncertain profitability normalization undermine the investment case.

Score
55
Applied Digital Corporation
APLD·Technology
D ★Strong Sell
Current$23.25
Oct 12, 2026

Applied Digital offers exceptional AI data center growth backed by long-term contracts, but heavy construction spending, leverage, and shareholder dilution threaten the conversion of that growth into sustainable per-share value.

Score
55
Cal-Maine Foods, Inc.
CALM·Consumer Staples
D ★Strong Sell
Current$66.67
Oct 3, 2026

Cal-Maine combines a debt-free balance sheet and growing specialty/prepared-food mix with dominant U.S. egg scale, but the current conventional-egg oversupply cycle has crushed margins and near-term earnings visibility.

Score
55
Bending Spoons S.p.A.
BSP·Technology
C ★★Sell
Current$39.11
Aug 15, 2026

Bending Spoons possesses a highly profitable M&A software roll-up model, yet organic growth is virtually stagnant at 3% and leverage constraints risk throttling the primary driver of its extreme valuation premium.

Score
55